Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6378583 | 0.94 | ALDH1A1 (0.54) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL3413225 | 0.91 | ALDH1A1 (0.57) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL8196611 | 0.88 | TDP1 (0.50) | ALDH1A1SLC1A1SMN1; SMN2TBXAS1 | |
| SCHEMBL9191601 | 0.86 | ALDH1A1 (0.51) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL9197596 | 0.86 | ALDH1A1 (0.54) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL24827422 | 0.85 | ALDH1A1 (0.57) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL9019803 | 0.85 | ALDH1A1 (0.50) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL21344787 | 0.85 | ALDH1A1 (0.65) | ALDH1A1SLC1A1 | |
| SCHEMBL9019848 | 0.84 | ALDH1A1 (0.47) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL14125262 | 0.83 | ALDH1A1 (0.51) | ALDH1A1SLC1A1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0806425-B1 | An improved regiospecific process for synthesis of acyclic nucleosides | LUPIN LAB LTD (IN) | 2001-08-29 | — | — | EP | claimed |
| US-5821367-A | REACTING A DIACYLGUANINE AND AN ALKYLATING AGENT IN THE ABSENCE OF AN ACID CATALYST AND A SOLVENT | LUPIN LABORATORIES LIMITED (IN) | 1998-10-13 | — | — | US | claimed |
| EP-0806425-A1 | An improved regiospecific process for synthesis of acyclic nucleosides | LUPIN LABORATORIES LIMITED (IN) | 1997-11-12 | — | — | EP | claimed |
| WO-2011114336-A1 | PROCESS FOR THE ISOLATION OF GANCICLOVIR INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-09-22 | — | — | WO | disclosed |
| US-7078524-B2 | Process for the synthesis of ganciclovir | RANBAXY LABORATORIES LIMITED (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050176956-A1 | Process for the preparation of ganciclovir intermediate n2-acetyl-9-(1,3-diacetoxy-2-propoxymethyl) guanine | RANBAXY LABORATORIES LIMITED (IN) | 2005-08-11 | — | — | US | disclosed |
| US-20040102628-A1 | Process for the synthesis of ganciclovir | RANBAXY LABORATORIES LIMITED (IN) | 2004-05-27 | — | — | US | disclosed |
| EP-0806425-B1 | An improved regiospecific process for synthesis of acyclic nucleosides | LUPIN LAB LTD (IN) | 2001-08-29 | — | — | EP | disclosed |
| US-6043364-A | HEATING THE ISOMER IN AN ALKYLATING AGENT IN ABSENCE OF ACID CATALYST AND SOLVENT | LUPIN LABORATORIES LIMITED (IN) | 2000-03-28 | — | — | US | disclosed |
| EP-0976751-A1 | A process for the isomerisation of an N-7 isomer into an N-9 isomer useful in the synthesis of acyclic nucleosides | LUPIN LABORATORIES LIMITED (IN) | 2000-02-02 | — | — | EP | disclosed |
| US-5821367-A | REACTING A DIACYLGUANINE AND AN ALKYLATING AGENT IN THE ABSENCE OF AN ACID CATALYST AND A SOLVENT | LUPIN LABORATORIES LIMITED (IN) | 1998-10-13 | — | — | US | disclosed |
| US-5821367-A | REACTING A DIACYLGUANINE AND AN ALKYLATING AGENT IN THE ABSENCE OF AN ACID CATALYST AND A SOLVENT | LUPIN LABORATORIES LIMITED (IN) | 1998-10-13 | — | — | US | disclosed |
| EP-0806425-A1 | An improved regiospecific process for synthesis of acyclic nucleosides | LUPIN LABORATORIES LIMITED (IN) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806425-A1 | An improved regiospecific process for synthesis of acyclic nucleosides | LUPIN LABORATORIES LIMITED (IN) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102628-A1 | Process for the synthesis of ganciclovir | TYMP, MTAP, TPMT | ALDH1A1 2906/4885SLC1A1 3371/4885CA1 3583/4885 |
| US-20050176956-A1 | Process for the preparation of ganciclovir intermediate n2-acetyl-9-(1,3-diacetoxy-2-propoxymethyl) guanine | GNE, MPG, B3GNT2 | ALDH1A1 1675/4885SLC1A1 3668/4885CA1 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.